Forward P/S Multiple: Beta Bionics (BBNX)
Beta Bionics Inc (BBNX) faces slow technology adoption and a dependence on insurance. However, robotic microelectronics assembly lines minimize defects. The forward P/S based on GURU.Markets forecasts utilizes data from the chart, where the latest parameter is 7.00, confirming the market valuation. Scaling sales of the iLet system creates operating leverage, significantly reducing per-unit production costs.
Summary analytical data breakdowns for Beta Bionics Inc (BBNX)
- market price and analyst price targets:
- company stock exchange capitalization indicators:
- issuer book value statistics:
- debt and liquidity data:
Total Debt to Capital Beta Bionics Inc|BBNX - Long-Term Debt to Equity Ratio|Short-Term Debt to Capital betabionics.com|BBNX - Company Aggregate Debts|Debt to Book Capitalization Ratio Beta Bionics Inc|BBNX - Company Long-Term Debt|Company Current Liabilities Beta Bionics|Quick Ratio betabionics.com
- financial results and valuation multiples details:
BBNX - Company Net Income|Expected Profit Beta Bionics Inc|BBNX - Market Cap to Net Income Ratio|Projected Price to Earnings iLet Bionic Pancreas|BBNX - PEG Multiple|EV/EBITDA Multiple Beta Bionics Corp|BBNX - Operating income before deduction of amortization|Earnings per share for the last twelve months Beta Bionics|BBNX - Earnings per one share for the last 12 months|Year-over-year earnings per share growth for the last twelve months betabionics.com|BBNX - Net earnings per share growth this year|Earnings growth forecast for next year Beta Bionics Inc
- sales and revenue indicators:
Fundamental company analysis:BBNX (Beta Bionics Corp)
The forward P/S reflects a scalability premium through the projected ratio of market capitalization to revenue. This metric measures market expectations for expansion, reacting to any changes in revenue generation rates. By analyzing the expected price-to-sales ratio, an investor determines the boundaries of the asset's fair value. For Beta Bionics Inc (BBNX), this indicator is critical, as pump distribution costs are temporarily outpacing operating cash flow.
Who Beta Bionics Inc competes with
Forward P/S Multiple BSX (bostonscientific.com)|EW: Market Cap to Projected Revenue|ResMed - Forward P/S Multiple|Market Cap to Future Revenue Ratio Insulet Corporation|ZBH: Forward P/S Multiple|COO - Market Cap to Expected Sales Ratio|ALGN (Align Corp) - Forward P/S Multiple|Globus Medical Corp (GMED) - Market Cap to Expected Sales Ratio|Forward P/S Multiple TMDX|Forward Price-to-Revenue Multiple Alphatec Holdings, Inc. ATEC|Forward P/S Multiple AORT (artivion.com)|Forward P/S Multiple Enovis Corp ENOV|IART - Price-to-Projected Revenue Ratio|ESTA: Price-to-Projected Revenue Ratio|IRMD (IRADIMED CORPORATION) - Forward Price-to-Revenue Multiple|Embecta Corp. - Forward Price to Sales|TNDM (Tandem Corp) - Forward P/S Multiple|Market Cap to Future Revenue Ratio AxoGen Inc AXGN|Price-to-Projected Revenue Ratio SI-BONE Inc (SIBN)|Orthofix Medical Inc. (OFIX) - Projected Price to Revenue|Forward P/S Multiple BVS (bioventus.com)|Forward P/S Multiple OrthoPediatrics Inc. KIDS|Treace Medical Concepts Inc - Forward P/S Multiple|Market Cap to Expected Sales Ratio Blade Air Mobility SRTA|Carlsmed (CARL) - Price-to-Projected Revenue Ratio|Future Price to Revenue RXST (RxSight Ophthalmic)|Price-to-Projected Revenue Ratio clearpointneuro.com|Forward Price-to-Revenue Multiple Stereotaxis, Inc. (STXS)|Forward P/S Multiple STIM|SGHT - Market Cap to Future Revenue Ratio|Price-to-Projected Revenue Ratio Orchestra BioMed, Inc. OBIO|ANIK: Market Cap to Projected Revenue|NSPR: Forward Price-to-Revenue Multiple|Jin Medical - Price to Expected Revenue Ratio|VANI (Vivani Medical Inc) - Forward Price-to-Revenue Multiple|Market Cap to Projected Revenue XTNT|NMTC (n1mtc.com) - Forward P/S Multiple|Market Cap to Future Revenue Ratio Modular Medical MODD|Price-to-Projected Revenue Ratio myomo.com (MYO)|Price-to-Projected Revenue Ratio COCH (envoymedical.com)|Price-to-Projected Revenue Ratio Vivos Therapeutics Inc VVOS|enVVeno Medical Corp. - Price-to-Projected Revenue Ratio|SINT: Forward Price-to-Revenue Multiple|TNON (Tenon Medical, Inc.) - Market Cap to Projected Revenue|Lifeward Ltd. (LFWD) - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio Autonomix (AMIX)|Price-to-Projected Revenue Ratio INVO Fertility|Bone Biologics Corp. (BBLG) - Market Cap to Expected Sales Ratio|Forward Price-to-Revenue Multiple AXNX (Axonics Modulation Technologies)|BIOL (Biolase, Inc.) - Forward Price to Sales|Forward P/S Multiple DYNT (dynatronics.com)|Forward Price to Sales FNA|INVO Bioscience - Forward P/S Multiple
